Gertsenshteyn, Inna
Epel, Boris
Ahluwalia, Amandeep
Kim, Heejong
Fan, Xiaobing
Barth, Eugene
Zamora, Marta
Markiewicz, Erica
Tsai, Hsiu-Ming
Sundramoorthy, Subramanian
Leoni, Lara
Lukens, John
Bhuiyan, Mohammed
Freifelder, Richard
Kucharski, Anna
Giurcanu, Mihai
Roman, Brian B.
Karczmar, Gregory
Kao, Chien-Min
Halpern, Howard
Chen, Chin-Tu http://orcid.org/0000-0003-2508-8726
Funding for this research was provided by:
National Cancer Institute (F31 CA254223, R01 CA098575, R01 CA 236385, P30 CA014599)
National Institute of Biomedical Imaging and Bioengineering (P41 EB002034)
National Institutes of Health (S10 OD025265, R01 EB029948)
Article History
Received: 3 March 2022
Accepted: 19 June 2022
First Online: 6 July 2022
Declarations
:
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.
: Author Chin-Tu Chen (CTC) is a PI for the following grants from NIH/NIBIB (R01 EB022388 and R01 EB029948), NIH/NIDA (R01 DA044760), and NIH/NCI (P30 CA14599 facility). CTC receives a personal fee from the American Institute of Physics for editorial responsibilities. Other relationships include institute licenses patents (CTC is a co-inventor) to RefleXion Medical, Inc. and Incom. CTC is a co-founder and on the board of directors of EVO Worldwide LLC and AEPX Imaging, Inc. Author Howard Halpern (HH) is a PI for the following grants from NIH/NCI (R01 CA098575 and P30 CA014599) and NIH/NIBIB (P41 EB002034). HH also holds two US patents (8,664,955 and 9,392,957) to him and one (9,392,957) to author Boris Epel (BE) for aspects of the pO<sub>2</sub> imaging technology; HH and BE are also members of a start-up company O2M to market the pO<sub>2</sub> imaging technology in preclinical models. No other potential conflicts of interest relevant to this article exist. The rest of the authors have no relevant financial or non-financial interests to disclose.